Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Restructuring Costs (2016 - 2020)

Tg Therapeutics has reported Restructuring Costs over the past 5 years, most recently at $16.2 million for Q4 2020.

  • Quarterly results put Restructuring Costs at $16.2 million for Q4 2020, up 452.33% from a year ago — trailing twelve months through Dec 2020 was $41.5 million (up 336.85% YoY), and the annual figure for FY2020 was $41.5 million, up 336.9%.
  • Restructuring Costs for Q4 2020 was $16.2 million at Tg Therapeutics, up from $11.6 million in the prior quarter.
  • Over the last five years, Restructuring Costs for TGTX hit a ceiling of $16.2 million in Q4 2020 and a floor of $1.1 million in Q1 2016.
  • Median Restructuring Costs over the past 5 years was $1.9 million (2018), compared with a mean of $3.5 million.
  • Biggest five-year swings in Restructuring Costs: dropped 8.02% in 2019 and later surged 452.33% in 2020.
  • Tg Therapeutics' Restructuring Costs stood at $1.3 million in 2016, then soared by 33.55% to $1.8 million in 2017, then dropped by 6.0% to $1.7 million in 2018, then soared by 76.04% to $2.9 million in 2019, then surged by 452.33% to $16.2 million in 2020.
  • The last three reported values for Restructuring Costs were $16.2 million (Q4 2020), $11.6 million (Q3 2020), and $8.6 million (Q2 2020) per Business Quant data.